Loading stock data…
$1.67+0.04 (+2.78%)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
Autolus Therapeutics plc in the Healthcare sector is trading at $1.67 with a market capitalization of $443M. Wall Street consensus targets $8.72 (8 analysts), implying a +424.0% move over the next 12 months. The stock is currently 35% below its 52-week high of $2.58, remaining 0.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $45.69M↑ | $26.22M↑ | $24.29M↑ | $21.19M↑ | $20.92M |
| Gross Profit | $25.22M↑ | $1.65M↑ | -$1.04M↑ | -$7.45M↓ | -$3.52M |
| Operating Income | -$43.84M↑ | -$59.51M↑ | -$72.47M↓ | -$71.62M↓ | -$61.22M |
| Net Income | -$39.11M↑ | -$71.60M↑ | -$90.33M↓ | -$79.12M↓ | -$47.92M |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consist...